Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • IBL, Tecan deal

    IBL International GmbH, Hamburg, Germany Tecan AG (SIX:TECN), Mannedorf, Switzerland Business: Diagnostic, Supply/Service Tecan will acquire IBL for EUR29 million ($38.9 million) in cash. Tecan said IBL, which markets …

    Published on 8/11/2014
  • Immco, Nicox deal

    Immco Diagnostics Inc., Buffalo, N.Y. Nicox S.A. (Euronext:COX), Sophia Antipolis, France Business: Ophthalmic Immco Diagnostics Inc., a part of Trinity Biotech plc (NASDAQ:TRIB, Dublin, Ireland), granted Nicox …

    Published on 8/11/2014
  • Immune Design, Sanofi deal

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Inflammation Immune Design granted Sanofi exclusive rights to discover, develop and commercialize products to …

    Published on 8/11/2014
  • Iroko, EMS deal

    Iroko Pharmaceuticals LLC, Philadelphia, Pa. EMS S.A., Sao Paulo, Brazil Business: Neurology Iroko granted EMS exclusive rights to commercialize pain drug Zorvolex submicron diclofenac in Brazil. EMS will be responsible…

    Published on 8/11/2014
  • Klox Technologies, Leo Pharma deal

    Klox Technologies Inc., Laval, Quebec Leo Pharma A/S, Ballerup, Denmark Business: Dermatology The partners created a JV to develop and commercialize Kloxs BioPhotonic technology platform for dermatology indications …

    Published on 8/11/2014
  • Myraqa, Illumina deal

    Myraqa, Redwood Shores, Calif. Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Business: Other Genomics company Illumina acquired Myraqa, a regulatory and quality consulting firm specializing in in vitro and companion …

    Published on 8/11/2014
  • Navidea, Rheumco deal

    Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB), Dublin, Ohio Rheumco LLC, Dover, Del. Business: Autoimmune Navidea and Rheumco formed a JV to develop and commercialize radiolabeled diagnostics and therapeutics for …

    Published on 8/11/2014
  • Northwestern University, Scripps Research Institute, Transplant Genomics deal

    Northwestern University, Evanston, Ill. The Scripps Research Institute, La Jolla, Calif. Transplant Genomics Inc., Brookline, Mass. Business: Diagnostic The Scripps Research Institute and Northwestern University granted…

    Published on 8/11/2014
  • Novartis, Banner Alzheimers Institute (BAI) deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Banner Alzheimers Institute (BAI), Phoenix, Ariz. Business: Neurology Novartis partnered with not-for-profit BAI to evaluate two of the pharmas compounds in …

    Published on 8/11/2014
  • Santaris, Roche deal

    Santaris Pharma A/S, Horsholm, Denmark Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Infectious Roche will acquire partner Santaris for $250 million in cash up front and up to $200 million in undisclosed …

    Published on 8/11/2014
  • Symplmed, Lannett deal

    Symplmed Pharmaceuticals LLC, Cincinnati, Ohio Lannett Co. Inc. (NYSE:LCI), Philadelphia, Pa. Business: Cardiovascular Symplmed granted Lannett exclusive rights to distribute an authorized generic of 2, 4 and 8 mg Aceon…

    Published on 8/11/2014
  • AstraZeneca, Roche deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Pharmacogenetics Roches Roche Molecular Diagnostics unit will develop a companion diagnostic for AstraZenecas …

    Published on 8/4/2014
  • Baxter, Pfizer deal

    Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Infectious Pfizer will acquire Baxters marketed vaccine portfolio for $635 million in cash. Baxters marketed …

    Published on 8/4/2014
  • Boehringer Ingelheim, Zealand Pharma deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Business: Cardiovascular, Endocrine/Metabolic Boehringer and Zealand partnered to discover and develop therapeutic peptide …

    Published on 8/4/2014
  • Cosmo, Valeant Pharmaceuticals deal

    Cosmo Pharmaceuticals S.p.A. (SIX:COPN), Lainate, Italy Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Montreal, Quebec Business: Dermatology Cosmo and Valeant amended an April 2012 deal that granted …

    Published on 8/4/2014
  • Eli Lilly, Anthera deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Business: Gastrointestinal Eli Lilly granted exclusive, worldwide rights to develop and commercialize Sollpura…

    Published on 8/4/2014
  • Evotec, Fraunhofer deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Fraunhofer-Gesellschaft, Munich, Germany Business: Neurology, Cancer Evotec partnered with the Fraunhofer Institute for Molecular Biology and Applied Ecology to conduct joint …

    Published on 8/4/2014
  • Gilead, Theraclone deal

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Theraclone Sciences Inc., Seattle, Wash. Business: Infectious Theraclone granted Gilead exclusive rights to develop and commercialize products incorporating …

    Published on 8/4/2014
  • Ipsen, Nestle deal

    Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Nestle S.A. (SIX:NESN), Vevey, Switzerland Business: Dermatology Ipsen and Nestles Galderma unit amended a 2007 deal to commercialize Ipsens Dysport …

    Published on 8/4/2014
  • J&J, Genmab deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Business: Autoimmune, Antibodies Genmab will receive a $3 million milestone payment from Johnson & Johnsons Janssen…

    Published on 8/4/2014
  • NeoGenomics, Path Labs deal

    NeoGenomics Inc. (NASDAQ:NEO), Fort Myers, Fla. Path Labs LLC, West Sacramento, Calif. Business: Supply/Service Cancer-focused genetic testing company NeoGenomics acquired Path Labs for $6 million in cash. Path Labs …

    Published on 8/4/2014
  • PharmaMar, Chugai deal

    PharmaMar S.A., Madrid, Spain Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Business: Cancer PharmaMar granted Chugai rights to promote Aplidin plitidepsin to treat multiple myeloma (MM) in the U.K., France,…

    Published on 8/4/2014
  • Qiagen, AstraZeneca deal

    Qiagen N.V. (Xetra:QIA;NASDAQ:QGEN), Venlo, the Netherlands AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Pharmacogenetics Qiagen will develop a companion diagnostic to identify patients that could benefit …

    Published on 8/4/2014
  • Roche, AmorChem deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland AmorChem L.P., Montreal, Quebec Business: Musculoskeletal Roche partnered with VC fund AmorChem to discover small molecules to treat myotonic muscular dystrophy type 1. …

    Published on 8/4/2014
  • Rottapharm Madaus, Meda deal

    Rottapharm Madaus Group, Monza, Italy Meda AB (SSE:MEDAA), Solna, Sweden Business: Pharmaceuticals Specialty pharma company Meda will acquire Rottapharm Madaus for SEK21.2 billion ($3.1 billion) in a deal slated to …

    Published on 8/4/2014

< Previous   1  2  3  4  5  6  7  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993